Navigation Links
Clinical Data & Innovation Will Shift PCI and CABG Procedures in Europe
Date:5/14/2009

By 2013, over 685,000 PCI and 165,000 CABG procedures will be performed, according to Millennium Research Group

WALTHAM, Mass., May 14 /PRNewswire/ -- According to two new Millennium Research Group (MRG) reports, emerging clinical data and innovations in device technology will shift the balance between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) procedures for unique subgroups with coronary artery disease through 2013. MRG's European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft Devices 2009 reports indicate that by 2013, over 685,000 PCI procedures and over 165,000 CABG procedures will be performed across Europe.

Results of clinical studies supporting the benefits of PCI will expand the eligible patient population to include higher-risk subgroups, which until recently have been untreated by PCI. In 2008, results of the CARDia trial identified similar rates of myocardial infarction, stroke, or death at 12 months in diabetic patients who received either PCI or CABG surgery. Initial results of the SYNTAX trial found the same trend for patients with complicated forms of CAD. Consequently, while CABG surgery will remain the gold standard treatment for complex CAD, some of these patients may now be considered eligible for PCI.

"Results of recent clinical studies demonstrate that PCI can be used to treat patients with significantly more complicated forms of CAD than previously thought possible," says Anuk Karunaratne, Senior Analyst at MRG. "Innovations in PCI technology -- such as improved stent design and intravascular ultrasound (IVUS) -- will enable treatment of more complicated cases and will allow PCI use to expand further into CABG territory, although it's unlikely that referral patterns will shift significantly in the short-term. Nevertheless, continued innovation and clinical data will influence physicians to select PCI as the optimal treatment for some higher-risk patients."

MRG's new reports, European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft (CABG) Devices 2009 cover France, Germany, Italy and the UK, and also provide data such as usage rates, units per procedure, average selling prices, and growth rates. Detailed market shares are provided across all market segments for key companies, including Abbott Vascular, Boston Scientific, Johnson & Johnson's Cordis, Medtronic, Sorin Group, Terumo Medical, Volcano, and more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: